<DOC>
	<DOCNO>NCT00878930</DOCNO>
	<brief_summary>The objective study obtain information Faslodex use treatment breast cancer clinical practice Argentina .</brief_summary>
	<brief_title>Parameters Acceptability , Compliance Efficacy Fulvestrant Post-menopausal Patients With Advance Breast Cancer</brief_title>
	<detailed_description>In Argentina , Faslodex indicate treat postmenopausal woman hormone receptor-positive locally advanced metastatic breast cancer recurrence adjuvant anti-oestrogen therapy disease progression anti-oestrogen treatment . This study provide information regard acceptability compliance Argentina patient Faslodex provide information regard efficacy treatment local population .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Postmenopausal woman hormone receptorpositive locally advanced metastatic breast cancer recurrence adjuvant antiestrogen therapy disease progression antiestrogen treatment , currently receive Faslodex Signature inform consent Any contraindication Faslodex administration</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Faslodex</keyword>
	<keyword>Acceptability</keyword>
	<keyword>Compliance</keyword>
	<keyword>Efficacy</keyword>
</DOC>